Navigation Links
McGill University Launches a Major New Study on HPV Prevention Using Divine 9 Personal Lubricants with Carragel
Date:1/7/2013

Orlando, Florida (PRWEB) January 07, 2013

Divine Corporation announced today its Divine 9® personal lubricant containing Carragel® has been selected by McGill University’s Division of Cancer Epidemiology for use in their large-scale, double-blind human trial on the ability of a personal lubricant with a special form of carrageenan gel to prevent the transmission of human papillomavirus (HPV). The study is called CATCH, an acronym for Carrageenan-gel Against Transmission of Cervical HPV, and will involve tracking HPV infections in over four hundred female volunteers for a one year period. Divine Corporation's unique carrageenan-based personal lubricant Divine 9 was the only personal lubricant selected for the trial due to earlier laboratory studies by the National Cancer Institute that showed it to be a strong inhibitor of HPV transmission. CATCH is funded by the Canadian Institutes of Health Research.

The McGill University research team is led by Dr. Eduardo Franco, Director of the Division of Cancer Epidemiology and is coordinated by Joseph Tota (PhD candidate). Dr. Franco, a renowned expert on the prevention of cervical cancer and HPV-associated diseases, has published over 300 scientific articles and spoken at over 300 conferences worldwide.

“The CATCH study is a major initiative to determine if using a carrageenan-based gel can prevent the acquisition and transmission of HPV in a real world setting,” explained Dr. Franco. “I’m extremely encouraged by the results of the laboratory studies by Dr. John Schiller’s team at the National Cancer Institute. If the trial is successful, it would mean that women have another option for protecting themselves against HPV, the causative agent for cervical cancer.”

The U.S. Centers for Disease Control considers HPV the most common sexually transmitted disease and estimates at least 20 million Americans are currently infected with the virus. Worldwide, approximately 257 million women are infected with HPV according to the World Health Organization.

While most HPV infections are cleared by the body naturally, those that do not can cause cancers of the cervix, anus, vulva, vagina, penis, tongue, tonsils and throat. Virtually all cases of cervical cancer are caused by persistent infections by specific types of HPV. The World Health Organization lists cervical cancer as the second-leading cause of female cancer fatalities worldwide, accounting for more than 250,000 deaths each year. More than 85 percent of these cases occur in developing countries. In addition to the cancer concerns, certain types of HPV cause genital warts on both men and women.

“To date, the options to fight the spread of HPV have been limited," explained Michael Swor, M.D., Chief Medical Officer at Divine Corporation. "Vaccines do not provide protection for women already infected by HPV and only work against either two or four of the more than one hundred HPV types, depending on which of the two available vaccines are used.”

A research team at the National Cancer Institute has conducted both in vitro (laboratory) and in vivo (animal) studies and found Divine 9 was highly effective in inhibiting infection rates. The possibility that Divine 9 with Carragel, applied before sexual contact, can block the transmission of HPV would be a breakthrough with worldwide medical significance. As a result, the Canadian Institutes of Health Research is funding Dr. Franco and his team to complete the CATCH study.

The CATCH study will recruit 465 female volunteers and each will be supplied with either Divine 9 personal lubricant or a placebo lubricant. The volunteers will use the personal lubricants whenever they are in intimate situations for a period of one year. During their monthly follow-ups, the women will visit designated clinics to determine their HPV infection rates.

“We have worked closely with Dr. Franco and his team at McGill University on this remarkable study to reduce HPV prevention using our special Carragel formulation contained in Divine 9 personal lubricant,” said Dean Fresonke, CEO of Divine Corporation. “With positive results, the world will have a powerful new weapon in the battle against cancer.”

About Divine Corporation

Divine Corporation is dedicated to improving your sexual wellbeing. Intensive research has led to a line of products formulated with the company’s proprietary carrageenan formula called Carragel®. Carragel is showing promise in its ability to block HPV infection in government-funded, independent laboratory studies. In addition to potential health benefits, Divine 9® delivers a sensual experience with its exotic, slippery feel that dries clean, never sticky. Look for Divine personal lubricants in health food stores, on-line drugstores such as Amazon.com and Drugstore.com, and other discriminating websites. Divine 9 with Carragel is “The Ultimate in Pleasure & Protection”® Learn more at http://www.divine9lubricants.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Hawkins 310-720-0215, jeff(at)divine9lubricants(dot)com

Read the full story at http://www.prweb.com/releases/Divine_9_Lubricants/McGill_Trial_on_HPV/prweb10281133.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The National Council on Problem Gambling and McGill Partner with Lotteries Worldwide to Discourage Lottery Gifts for Minors
2. Hospital of the University of Pennsylvania receives Comprehensive Stroke Center Certification
3. High Fat Diet Tied to Increased Diabetes Risk Nature according to University of Massachusetts study reviewed by Naturecast Products
4. True Dose Launches ‘Web University’ of its Products
5. 56 percent of female university students get drunk in record time
6. Rush University Medical Center scientists home in on cause of osteoarthritis pain
7. Case Western Reserve University receives patient-centered research award
8. The Hong Kong Polytechnic University promotes knowledge enterprises through MAKE Award
9. A Serious Problem: Medical Malpractice Lawyers at Console & Hollawell React to Alarming Doctor Error Statistics from Johns Hopkins University Researchers
10. AED.com Donates LifePak CR Plus AED to Tennessee State University Athletic Department
11. University Hospitals Neurological Institute to present 6th International 2013 Epilepsy Colloquium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... provide care from the clinic, which opened March 22, 2017. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the ... create a communications platform that positions them as the go-to thought leader in ... their online publication as an always-on, always-fresh news, views and advocacy engine, called ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian ... Bible teacher residing in North Carolina with his wife, Anna Marie. He and his ... six grandchildren. David is also the author of “Shadow and Substance.” , “Love, the ...
(Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... -- Executive Summary ... research (inputs from industry experts, companies, stakeholders) and ... analysis of global heart valve devices market on ... Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter Aortic Valve ... Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), By Region ...
(Date:3/23/2017)... SPRING, Md. , March 23, 2017  The ... to Bavencio (avelumab) for the treatment of adults and ... cell carcinoma (MCC), including those who have not received ... metastatic MCC, a rare, aggressive form of skin cancer. ... most common cancers, patients with a rare form called ...
(Date:3/23/2017)... and VANCOUVER, British Columbia ... SPHS ) (the "Company" or "Sophiris"), a ... treatment of urological diseases, today announced that data from ... the drug as a focal treatment for localized prostate ... 26, 2017 at the 32 nd Annual European ...
Breaking Medicine Technology: